January 27, 2017 06:31 AM ESTUpdated January 30, 03:27 PM
News Briefing

No­var­tis silent­ly yanks a trou­bled biosim­i­lar ap­pli­ca­tion; Chi­nese an­ti­body de­vel­op­er draws $39M round

Shehla Shakoor

Managing Director

• No­var­tis nev­er has tried to ex­plain why the FDA has re­ject­ed its biosim­i­lar of Am­gen’s Neu­las­ta. And it’s be­ing equal­ly ret­i­cent about its de­ci­sion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times